“Advancing Patient-centered Care” in GPP: Spesolimab (Spevigo, Boehringer Ingelheim) Improves Physical Symptoms, QofL

March 9, 2025

Deucravacitinib’s Safety and Efficacy Holds in Five-Year PsO Study

February 25, 2025

Expert Guidance on the Use of Deucravacitinib (Sotyktu, BMS) in PsO

February 11, 2025

News Your PsO Patients Can Use: Guselkumab Shows Significant Skin Clearance in Special Sites

February 6, 2025

Study: One in Four Psoriasis Patients Show Early Signs of Psoriatic Arthritis

September 16, 2024

Now Available: Otezla for Kids With Moderate to Severe Psoriasis

August 20, 2024

Now Available: NPF’s Psoriasis Health Indicator Report

August 16, 2024

Is It Time to Escalate Your Psoriasis Patient’s Treatment Regimen?

August 13, 2024

Understanding CARD14’s Role in Skin Barrier Function: Implications for AD and Psoriasis

August 12, 2024

Are Black Patients More Likely to Undergo a Skin Biopsy for Psoriasis?

August 8, 2024

FDA Approves Alembic’s Generic Acitretin Capsules USP, 10mg, 17.5mg, and 25mg

August 7, 2024

Get Involved: NPF Launches Annual Take ACTION Campaign for Psoriasis Action Month

August 1, 2024